ReviewNature cancer2026
Harnessing myeloid cell plasticity for cancer therapy.
Review in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-driven immunosuppression in cancer.Cell insight · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid cells have a multifaceted role in cancer, promoting tumor progression through angiogenesis, metastasis and immune suppression, as well as stimulating antitumor immunity. Traditionally, this dual functionality was attributed to cell heterogeneity, but it appears that myeloid cell plasticity is a more fundamental cancer trait. In this Review, we discuss two types of plasticity that enable myeloid cells to adjust to the tumor environment: differentiation plasticity, characterized by increased myelopoiesis and shifting differentiation patterns, and functional plasticity, marked by the adoption of pathological activation states. We assess the challenges to myeloid cell targeting in cancer and propose adaptable therapeutic strategies to overcome them.
Indexed as
Identifiers
42120911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.